GlaxoSmithKline Czech Republic made a net profit of CZK CZK 125 mil under revenues of CZK 4,378 mil in 2015, up 42.1% and -9.83%, respectively, when compared to the last year.
This translates into a net margin of 2.85%. Historically, the firm’s net margin reached an all time high of 4.12% in 2011 and an all time low of -0.197% in 2006. The average net margin in the last five years amounted to 2.78%.
On the operating level, EBITDA margin reached 2.91% and EBIT amounted to 3.17% of sales in 2015.
As far as GlaxoSmithKline Czech Republic's peers are concerned, Roche Czech Republic posted net and EBITDA margin of 0.936% and 3.84%, respectively in 2015, Bayer Czech Republic generated margins of 2.89% and 3.93% and Amgen Czech Republic's profit margin reached 5.93% on the net and 7.66% on the EBITDA level in 2015.